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Abstract: The 3,5-dimethylisoxazole motif has become a useful and popular acetyl-lysine mimic employed
in isoxazole-containing bromodomain and extra-terminal (BET) inhibitors but may introduce the potential
for bioactivations into toxic reactive metabolites. As a test, we coupled deep neural models for quinone
formation, metabolite structures, and biomolecule reactivity to predict bioactivation pathways for 32 BET
inhibitors and validate the bioactivation of select inhibitors experimentally. Based on model predictions,
inhibitors were more likely to undergo bioactivation than reported non-bioactivated molecules containing
isoxazoles. The model outputs varied with substituents indicating the ability to scale their impact on
bioactivation. We selected OXFBD02, OXFBD04, and I-BET151 for more in-depth analysis. OXFBD’s bioac-
tivations were evenly split between traditional quinones and novel extended quinone-methides involving
the isoxazole yet strongly favored the latter quinones. Subsequent experimental studies confirmed the
formation of both types of quinones for OXFBD molecules, yet traditional quinones were the dominant
reactive metabolites. Modeled I-BET151 bioactivations led to extended quinone-methides, which were
not verified experimentally. The differences in observed and predicted bioactivations reflected the need
to improve overall bioactivation scaling. Nevertheless, our coupled modeling approach predicted BET
inhibitor bioactivations including novel extended quinone methides, and we experimentally verified those
pathways highlighting potential concerns for toxicity in the development of these new drug leads.
Keywords: bromodomain; inhibitor; isoxazole; model; deep neural network; pathway; bioactivation;
reactive metabolite; quinone; glutathione
1. Introduction
Targeted cancer therapeutics boast superior health outcomes relative to traditional
chemotherapy drugs; however, hepatotoxicity poses a major clinical concern for patients
undergoing treatment with those drugs [1–4]. A well-established initiating event, especially
for idiosyncratic drug-induced liver injury, is the metabolic bioactivation of drugs [5–7].
Assessment of the drug bioactivation risk traditionally relies on experimental studies incur-
ring high costs in time, effort, and resources as well as expertise. To mitigate this expense,
we have developed metabolism and bioactivation models to increase the efficiency of drug
development. First, we designed deep neural models to predict the formation of specific
reactive metabolites including epoxides [8] and quinone species [9], and the bioactivation of
structural alerts such as furans, phenols, nitroaromatics, and thiophenes [10]. Importantly,
the quinone model is capable of predicting the formation of other reactive metabolites
within the broader class of conjugated electrophiles, despite its name. Second, we recently
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reported a novel approach for predicting the structures of metabolites arising from bioacti-
vations [11]. The information could facilitate their experimental identification as well as the
construction of possible metabolic pathways. Third, the toxicological relevance of reactive
metabolites often depends on the ability to adduct with and modify biological molecules,
such as proteins, glutathione, and DNA [12–14], and therefore, we developed models to
predict adduct formation [9,15]. These computational analyses are more accessible than
experiments and provide an opportunity to readily explore potential relationships between
molecular structure and bioactivation that lead to testable hypotheses. In practice, we cou-
ple high throughput computational studies with experimental efforts to validate predicted
relationships and reveal model shortcomings for further refinement into practical tools, as
shown through our work on terbinafine [16], thiazoles [17,18], and diphenylamine nons-
teroidal anti-inflammatory drugs [19]. In this study, we applied our novel computational
and experimental strategy to reveal the potential bioactivation liabilities of bromodomain
and extra-terminal (BET) inhibitors.
BET inhibitors comprise a growing class of anti-cancer agents, [20,21] including at least
24 drug candidates in Phase I clinical trials [22–24]. These molecules target proteins that possess
bromodomains, which are modules that are capable of binding acetylated lysine residues present
on histones and many other proteins [25,26]. That action regulates the transcription of oncogenes
and anti-apoptotic proteins [22,27]. Consequently, molecules mimicking the modified amino
acid are effective at disrupting the bromodomain functions in cancer cells. A number of BET
bromodomain inhibitors, including I-BET151, incorporate the 3,5-dimethyl-isoxazole motif as
an isostere of acetyl-lysine for its mode of action [28–33]. I-BET151 shows efficacious inhibition
against leukemic cell line proliferation [33,34] and has progressed to clinical trials [35]. Similar to
other early BET inhibitors, I-BET151 induces unwanted toxic side effects that are often attributed
to low selectivity amongst different bromodomains and other toxic mechanisms based on elevated
liver enzyme and bilirubin levels that are indicative of drug-induced liver injury [36,37]. New
generations of BET inhibitors seek to capitalize on the 3,5-dimethylisoxazole motif [28–32,38–46]
and incorporate more molecular diversity to improve bromodomain (BRD) selectivity, such as
between BRD1 and BRD2. This strategy could potentially reduce pan-BET inhibitor-associated
side effects yet the risks for other adverse outcomes, such as drug-induced liver injury, may persist.
Isoxazole metabolism and bioactivation resulting in toxicity is rare [47] but possible. Isoxazole
substituents might potentiate bioactivation risks in which the metabolism generates reactive
conjugated electrophilic metabolites, such as cyanoacroleins [48,49] or enimines [50,51], that react
with glutathione. To our knowledge, there are no investigations of these types of bioactivations or
others for isoxazole-containing BET inhibitors. We hypothesized that coupling our bioactivation,
metabolite structure, and reactivity deep neural models would predict bioactivation pathways for
the 3,5-dimethyl-isoxazole motif present in BET inhibitors.
Herein, we carried out a novel coupled modeling strategy to predict bioactivation path-
ways involving isoxazoles and validated them experimentally for selected BET inhibitors
that are currently in development. The identification of possible bioactivation pathways for
isoxazoles involved coupling deep neural models for quinone species formation, metabo-
lite structures, and then biomolecule reactivity, as described previously [19]. Next, we
assessed the capacity of our quinone model to identify potential electrophilic metabolites
generated for isoxazole-containing molecules in the Accelrys Metabolite Database (AMD).
For select molecules, bioactivation outputs were used to predict the metabolite structures
from reactions and then, reactivity with glutathione. As a practical application of this
approach, we predicted possible bioactivation pathways for 32 isoxazole-containing BET
inhibitors varying in molecular structure and selectivity toward the first bromodomain
of bromodomain containing protein 4 (BRD4(1)) [28,52]. Subsequently, we selected the
following two promising drug leads: OXBFD02 and OXBFD04. These molecules differ
in the substitution of a phenyl group, with pyridine leading to a significantly enhanced
half-life and the affinity of BRD4(1) for OXFBD04 relative to OXFBD02 [28]. In this analysis,
we also included I-BET151, which is representative of a promising first generation BET
inhibitor [34,53], that may undergo bioactivation. We carried out metabolism studies with
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those molecules using human liver microsomes. Reactions included dansylated glutathione
to trap reactive metabolites and track adducts using the fluorescent dansyl tag [19,54,55].
A subsequent mass spectrometric (MS) characterization of the glutathione adducts pro-
vided a way to infer structures of the observed reactive metabolites. When combined
with the observed reaction metabolites, we were able to construct putative bioactivation
pathways for the BET inhibitors and then compare the findings to model predictions.
2. Results
2.1. Mining the Accerlys Metabolite Database for Possible Isoxazole Bioactivations
Given the limited examples of isoxazole bioactivations in the literature, we mined ex-
amples of molecules and reactions present in the AMD for a broader assessment of possible
bioactivations. Of the 20,736 parent molecules, we found 344 isoxazole-containing molecules.
Of the 344 isoxazole-containing molecules, 12 formed electrophilic conjugated systems via
two different reaction mechanisms involving the isoxazole (Figure S1). Using ECFP6-derived
fingerprints, the set of 344 isoxazole-containing molecules and the subset of 12 bioactivated
molecules each had high internal diversities [56] of 0.85 and 0.70, respectively, indicating the
representation of a variety of different molecular structures. The subset of 332 non-bioactivated
molecules had a low similarity to the nearest neighbor [56] from the bioactivated subset of 0.212.
Two molecules involved the oxidation of the isoxazole fused to another ring, that ultimately
led to cleavage of the isoxazole (Figure S1A). The resulting diketo metabolite may be reactive
due to conjugation with an adjacent double bond. The inferred metabolite for one molecule is
known to be reactive with glutathione, while the metabolites for the other molecule have no
evidence of reactivity towards glutathione (Figure S2). The ten other electrophilic conjugated
systems involved a 4-amino-5-methyl-isoxazole bioactivated into an enimine (Figure S1B) and
all of them were reactive toward glutathione at the methyl group, emphasizing a pattern of
bioactivation and reactivity.
2.2. Assessment of Model Accuracy to Predict Electrophilic Conjugated Systems Involving Isoxazoles
The identification of bioactivated 4-amino-5-methyl-isoxazoles provided a test set for
assessing the ability of coupled models to predict complete bioactivation pathways for en-
imine formation, metabolite prediction, and biomolecular reactivity. We then assessed model
accuracy toward predicting the occurrence and sites of bioactivations for isoxazole-containing
molecules within AMD (Figure 1A). First, model predictions identified molecules known to
undergo bioactivation with an AUC of 0.90 (0 to 1.0 scale) (Figure 1B) with two exceptions
in which bioactivation led to the cleavage of the isoxazole (Figure S2). These findings con-
trasted with very low predictions for isoxazoles that did not undergo bioactivation, indicating
the ability of the model to distinguish between the two possibilities. Second, the model
accurately predicted which atoms are the sites of metabolism, leading to the enimine for all
ten molecules possessing the 4-amino-5-methyl-isoxazole. Given those positive results, we
inferred molecular structures for the corresponding reactive metabolites (Figure 1C). The algo-
rithm predicts many possible metabolite structures; therefore, we scaled their likelihood based
on the associated highest atom-pair score from the quinone formation model and reported
the most probable one as shown in Figure 1D. This approach led to the correct identification
of the experimentally identified reactive metabolites for all ten molecules, whose 4-amino-5-
methyl-isoxazole group underwent conversion into an enimine (Figures S3 and S4). Third,
we predicted the reactivity of those isoxazole enimines with glutathione. As expected, all ten
metabolites were highly reactive with glutathione at the correct site of adduction. Further
substituent analysis also revealed that the model predictions align with common knowledge
of metabolism and bioactivation, namely the deactivating effects of a phenyl to a pyridine and
methyl to ethyl substitutions [57] (Figures S5 and S6). Taken together, the coupling of models
provided accurate predictions of 4-amino-5-methyl-isoxazole bioactivations, the resulting
metabolites, and subsequent reactivity toward glutathione.
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Figure . uinone model predictions for bioactivation of is xazole-containing molecules (A) Compounds with an isoxazole
ring, shaded in grey, can be metabolized into reactive electrophiles such as the illustrated enimine. (B) The quinone
model identifies which isoxazole-containing molecules will undergo bioactivation into a conjugated electrophile involving
the isoxazole ring with 90% AUC accuracy. The histogram uses normalized frequencies; therefore, the scale is balanced
for the 332 negative (not bioactivated) molecule predictions and the 12 positive (bioactivated) molecule predictions.
(C) The quinone structure inference model can generate possible quinone and enimine metabolite structures for a queried
compound. (D) For all 10 enimine-forming molecules, the quinone structure inference model correctly predicts the reported
metabolite structure when using the highest atom-pair probability. (E) Likelihood of conjugated electrophile formation
among drug leads for bromodomains, predicted using the quinone model with two types of assessment (see text).
2.3. Application of Coupled Modeling Approach to Predict Bioactivation of BET Inhibitors
Given the importance of BET inhibitors, we used our coupled modeling approach to
predict the reactive metabolites and potential for glutathione conjugation for 32 bromodomain
inhibitors containing 3,5-dimethyl isoxazoles [28,30,31] (Figures S7 and S8). The quinone model
predicted that the inhibitors had an elevated relative risk of 2.7 (p-value < 0.001) for undergoing
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bioactivation relative to the isoxazole-containing molecules from our original validation set
that do not undergo those reactions (Figure 1E). However, the inhibitors also had a lower
relative risk of 0.45 compared to positive controls (p-value < 0.01). Based on the appropriate
scaling of quinone model scores to actual probabilities [9], we interpret this trend to mean these
molecules are of elevated bioactivation risk and, thus, this outcome prompted our subsequent
experimental investigation to validate the predictions. The quinone model predictions also
demonstrate general, expected trends for substituent effects promoting quinone formation
(Figure S7). Specifically, the modification of the distal phenyl group with methoxy groups
decreased bioactivation, while fluorine and chlorine atoms had no effect on the bioactivation
potential, regardless of the position on the ring. Lastly, the substitution of that phenyl group
with pyridine led to a general decrease in the overall bioactivation predictions.
For more in-depth analyses, we chose three inhibitors for modeling possible metabolic
pathways and validating them experimentally. Specifically, we selected an earlier genera-
tion BET inhibitor, I-BET 151 [34,53], and in-development drug leads [28],
OXFBD02 and OXFBD04, which differ only in the presence of a phenyl substituent
versus pyridine, respectively. The quinone model predicted molecule-level bioactiva-
tion scores of 0.59 (OXFBD02), 0.51 (OXFBD04), and 0.54 (I-BET151). The substitution
between OXFBD02 and OXFBD04 then led to a slight decrease in bioactivation. Ap-
plication of the structure inference model indicated that all three of the inhibitors un-
derwent bioactivation into a quinone species, including a surprising subset involving
the isoxazole ring. These quinone species are novel in comparison to the enimines
observed for the AMD set of molecules; however, the formation of those reactive
metabolites is not possible for these compounds. To infer and rank the most probable
quinone metabolite structures, we used the more reliable atom-pair score for metabolites
(Figure 1B) instead of the atom scores, despite the equivalent AUC performance
(Figure S9). This performance difference may reflect unlikely outcomes, such as di-
ene formation with both methyl groups when only using atom scores. Furthermore,
atom-pair predictions that do not correspond to an inferred structure produced by the
structure inference model are discarded and the retained predictions, which map to an in-
ferred quinone structure, are ranked. We predicted glutathione adduct structures for the
corresponding quinone species with the highest atom-level reactivity score, and inferred
possible bioactivation pathways for OXFBD02, OXFBD04, and I-BET151, as shown in
Figure 2 and Figure S10. The number of reported pathways of the most probable quinone
metabolites and their most probable adducts was expanded to include all of the experi-
mentally observed metabolites from the parent molecules, with a minimum of the three
top pathways if the parent molecule had no experimentally observed metabolites. The
highest predictions for bioactivations were relatively low and did not vary significantly
when yielding different reactive metabolites. Moreover, the resulting metabolites with
conjugated systems possessing a methylene were more reactive with glutathione than
quinones in all cases.
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bioactivation pathways for OXFBD02. The top six pathways split evenly between traditional (Q) and extended quinone-
methides (EQ) involving the isox zole and are ranked based on the in ic d quinone mod l scor . EQs were highly reactive
to glutathione but traditional quinone reactivity was only moderate to low, as reflected in the reactivity prediction values.
Dashed arrows denote the transformations for which the predictions are below the model’s binarization threshold. Stars
show the predicted glutathione adducted metabolites observed experimentally (Figure 3). (B) The top six pathways split
evenly between traditional (Q) and extended quinone-methi s (EQ) and are r nked based on the indicated quin ne model
score. EQs were highly reactive to glutathione but traditional quinone reactivity was only moderate to low, as reflected in
the reactivity prediction values. Dashed arrows denote the transformations for which the predictions are below the model’s
binarization threshold. Stars show the predicted glutathione adducted metabolites observed experimentally (Figure 3).
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Figure 3. Competing bioactivation pathways for OXFBD series of BET inhibitors. OXFBD02′s and OXFBD04′s bioactivation
pathways require an initial hydroxylation of the internal phenyl group. The three potential sites give rise to three competing
pathways, as indicated by circled numbers. Pathways 1 and 2 show hydroxylations yielding an ortho-hydroquinone.
Pathw y 1 leads to an ortho-quinon and a subsequent p ir of glutathione adduct isomers (A1a and A1b). In contrast,
Pathway 2 bifurcates, leading to either an ortho-quinone and a pair of glutathione adduct isomers (A2a and A2b), or a
single glutathione adduct arising from an extended quinone-methide involving the isoxazole (A4). Pathway 3 involves
an initial formation of a para-hydroquinone followed by a para-quinone trapped into a pair of glutathione adduct isomers
(A3a and A3b). Analysis of adducts then yields characteristic patterns for pairs of quinones except for the extended quinone
in which there is one possibility.
2.4. OXFBD02 Und rwent Extensive Metabolism and Bioactivation Dow Competing Pathways
Based on Experimental Studies
In general, the OXFBD02 bioactivations with microsomal reactions involved sequential
oxidations, leading to the formation of quinone species trapped by dansyl glutathione.
As shown in Figure 3, an initial hydroxylation of OXFBD02 creates three pathways lead-
ing to mono-hydroxylated metabolites (M1, M2, and M3) that can undergo further ox-
idation into quinone species (Q1, Q2, and Q3) and, in one case, an extended quinone-
methide (EQ). Pathways 1 and 2 reflect hydroxylation yielding an ortho-hydroquinone.
Pathway 1 leads to an ortho-quinone and, subsequently, a pair of glutathione adduct isomers
(A1a and A1b). In contrast, Pathway 2 bifurcates, leading to either an ortho-quinone and a
pair of glutathione adduct isomers (A2a and A2b), or a single glutathione adduct arising
from an unusual extended quinone-methide (A4). Pathway 3 involves an initial formation
of a para-hydroquinone followed by a para-quinone trapped in a pair of glutathione adduct
isomers (A3a and A3b). Taken together, the occurrence of all of the pathways would lead
to a 2:2:2:1 pattern of chromatographically resolved adduct peaks.
Experimental studies revealed an extensive metabolism of OXFBD02 based on chromato-
graphic resolution and the combined detection of analytes by fluorescence and MS. The absence
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of an NADPH-regenerating system (negative control) indicated many background fluorescence
signals from the dansyl glutathione reagent or other reaction constituents (Figure 4A). The
complete reaction led to multiple new peaks in a 2:3:1 pattern that increased over time, as
expected for metabolites. All of the peaks were presumably dansylated glutathione adducts,
given that the parent molecule was spectrally silent under detection conditions. In support
of that possibility is the elution of those peaks after the dansyl glutathione trap, as reported
for adducts in other studies [19,54,55]. MS analysis of analytes provided further evidence for
OXFBD02′s bioactivation into adducted quinone species. The initial total ion scans indicated
OXFBD02′s (295 m/z) oxidation into five mono-hydroxylated metabolites (311 m/z) and three di-
hydroxylated metabolites (327 m/z) (Figure 3 and Figure S11). These hydroxylated metabolites
underwent further oxidation, leading to a reactive quinone species and the extended-quinone
methide trapped by dansyl glutathione.
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Figure 4. Fluorescence and MS hromatograms of putative quinone adducts for OXFBD02 and OXFBD04 from human
liver microsomal reacti ns. (A) OXFBD02 was bioactivated into six fluorescently and mass spectroscopically detectable
dansyl-glutathione adducted quinone-species metabolites. (B) OXFBD02 was bioactivated into three fluorescently and
mass spectrometrically detectable dansyl-glutathione adducted quinone-species metabolites. In both panels, data displayed
on the plot are as follows: no metabolic reaction (negative control, pink dotted line), 30 min reaction with fluorescence
detection (blue solid line), 60 min reaction with fluorescence detection (black solid line), and 60 min reaction with mass
detection (green solid line). The left Y-axis corresponds to data collected from fluorescence detection, whereas the right
Y-axis corresponds to data collected from mass detection. Adduct identities are labeled according to the naming strategy
displayed in Figure 3 and based on patterns of eluted adducts, as discussed in Results.
Product ion mass spectrometry analyses confirmed the expected parent masses and iden-
tified the characteristic fragments for the expected adducts. As observed by fluorescence
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(Figure 4A), scans for the adduct total ion mass of 849 m/z revealed a chromatographic resolution
of three analyte clusters. There was a doublet of peaks followed by a triplet and then a single,
late-eluting peak, suggesting the formation of adduct isomers. All of the analytes possessed the
742 m/z product ion after loss of the characteristic phenoxymethyl group for OXFBD02, indicat-
ing that none of the adducts involved the oxidation of that group. Moreover, putative adducts
yielded the following signature product ions from the fragmentation of dansyl glutathione:
234, 252, 361, 378, 487, 505, and 539 m/z (Figure 5) [54,55]. Nevertheless, none of the product
ions were distinguishing features among ortho- and para-quinone isomeric adducts or even that
for the extended quinone adduct. We then leveraged the chromatographic 2:3:1 pattern for the
eluted adducts to infer their identification (Figure 4A,B). We inferred that the triplet of analytes
reflected overlapping elution of the two doublets of ortho-quinone adducts (A1a/b and A2a/b)
due to significant structural similarities. The larger central peak corresponded to the additivity
of fluorescence and mass responses for the co-eluted ortho-quinone adducts. The preceding peak
doublet reflected the pair of para-quinone adducts (A3a/b). Finally, the lone, smaller, late-eluting
peak was presumably the single extended quinone-methide adduct. Its elongated structure
would interact more strongly with the C18 column than the other adducts, resulting in the
longest observed retention time. Definitive evidence for adduct identities would require nuclear
magnetic resonance spectroscopy, which is beyond the scope of this study. Nevertheless, the
combination of fluorescence and mass responses with the chromatographic pattern of elution
indicated that OXBFD02 underwent bioactivation, mainly into reactive ortho- and para-quinones
and, to a lesser extent, an atypical extended quinone-methide.Metabolites 2021, 11, x FOR PEER REVIEW 10 of 20  
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2.5. Metabolism and Bioactivation of OXFBD04 Was Very Limited According to Experimental Studies
The possible metabolic pathways for OXFBD04 are superficially the same as those for
OXFBD02 based on their structural similarities (Figure 3). Nevertheless, substitution of a phenyl
group with pyridine led to significantly different extents of metabolism and bioactivation. The
fluorescence chromatogram from the human liver microsomal reactions indicated no distin-
guishing peaks from the background (Figure 4B) yet labeled adducts could be beyond the
limits of detection and/or co-eluting with background peaks. Complementary total ion scans
showed that OXFBD04 (296 m/z) underwent metabolism into only two mono-hydroxylated
metabolites (312 m/z) (Figure S12). Initial scans of the proposed quinone species and extended
quinone-methide adduct, with total ion masses at 850 m/z, yielded a 2:1 pattern with two peaks
of similar intensity followed by a smaller third one (Figure 4B). Product ion mass spectrometry
resulted in several characteristic dansyl glutathione fragments (324, 487, 505, and 539 m/z) for
putative trapped quinone species adducts (Figure 6), albeit with less abundant responses than
those observed for the OXFBD02 adducts. As with OXFBD02, no product ions were distin-
guishing features among the possible adducts. Nevertheless, the elution pattern was consistent
with a pair of quinone adduct isomers followed by the extended quinone-methide adduct. The
identity of the isomeric adducts are likely to be A2a/b due to their origination from the same
mono-hydroxylated metabolite (M2). In following, OXFBD04 seems to preferentially undergo
metabolism and subsequent bioactivation down a single pathway among three possibilities.
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generated during the metabolism of I-BET151 as a function of time (Figure S13). The
subsequent total ion scans showed elution of the parent drug (417 m/z) and two mono-
hydroxylated metabolites (433 m/z) (Figure S14), but no observable di-hydroxylated
or tri-hydroxylated metabolites. Moreover, total ion mass spectrometry revealed no
peaks corresponding to predicted parent masses for 952 or 984 m/z corresponding to
possible glutathione-reactive quinone species metabolites from I-BET151 metabolism.
Taken together, MS and fluorescence analyses failed to reveal any evidence for a quinone
species adduct, suggesting that I-BET151 does not undergo bioactivation.
3. Discussion
3.1. Quinone Model Predictions for Reactive Non-Quinones Involving
4-Amino-5-Methyl-Isoxazole
Despite its name, our quinone model was able to predict the bioactivation of molecules
containing 4-amino-5-methyl-isoxazole into rare, and yet observed, enimines [50,51]. This
new finding suggests that our model has utility in identifying undiscovered metabolites and
the impact of substituents on those outcomes. Those results did not reflect model bias from
the training set. The high diversity in structure within and between test and training sets
made that possibility unlikely. In fact, diversity in the training data has taught the model
to adjust the magnitude of predictions due to alkyl substituent effects. The replacement of
the methyl with an ethyl group on the isoxazole decreased the model scores. This effect
reflects the hindrance of the orbitals of the ethyl group to adopt the ethene structure versus
methylene for the methyl group, as observed in the reported isoxazole enimines. Moreover,
the model accurately predicted a decrease in the bioactivation potential between phenyl
and pyridine to form quinones when attached to the isoxazole. The trend might reflect
the impact of the electron withdrawing nature of the pyridine nitrogen, which suppresses
oxidation typically by cytochromes P450 [57–59]. After the bioactivation of the 4-amino-5-
methyl isoxazole, the exposed methylene was very reactive and was targeted for adduction
by glutathione, as reported in the literature [50,51]. These data demonstrated the potential
for the quinone model to predict unexpected reactive metabolites other than the traditional
quinones within the broad class of conjugated electrophiles and, thus, could have more
applications in predicting bioactivations.
3.2. Modeled Bioactivations of the 3,5-Dimethyl Isoxazole Present in BET Inhibitors
As a practical application, we predicted the bioactivation of a series of 32 established
and under-development BET inhibitors to determine whether 3,5-dimethyl isoxazole was
able to form a reactive metabolite. The isoxazole lacks the 4-amino group, which played
a critical role in the previously reported isoxazole bioactivations [50,51]. For this test
set, all of the inhibitors displayed a decreased bioactivation risk relative to the molecules
known to form enimines. This finding suggests that the 4-amino group on the isoxazole
favored bioactivation according to the model. While 3,5-dimethyl isoxazole led to a lower
bioactivation potential, the modeled likelihoods were greater than that for isoxazole-
containing molecules contained within AMD that do not undergo bioactivation. The model
scores varied with substituents on the distal phenyl ring indicating the ability of the model
to scale their impact on bioactivation. Specifically, methoxy groups decreased bioactivation,
while fluorine and chlorine atoms had no effect regardless of their position on the ring.
In addition, the substitution of that phenyl group with pyridine led to a general decrease
in the overall bioactivation predictions. These differences may reflect effects or a lack of
effects on chemical reactions as well as enzyme specificities but require further study to
validate the trends and determine the underlying causes. Consequently, we selected three
of these BET inhibitors, namely, OXFBD02, OXFBD04 (in-development drug leads) [28],
and I-BET151 (first generation BET inhibitor) [34], for more in-depth modeling analyses
and, importantly, confirming the predicted bioactivations with experimental studies.
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3.3. Metabolism and Bioactivation of OXFBD02 and 04, but Not I-BET151, into Quinones
The molecular structures of the selected inhibitors impacted the bioactivation possi-
bilities and subsequent interpretation of the findings. OXFBD02 and 04 share a common
isoxazole-phenyl scaffold and differ only in the presence of an additional distal phenyl
or pyridine substituent, respectively. For the OXFBD molecules, the structural difference
led to a 10-fold increase in metabolite stability for OXFBD04 over OXFBD02 in a half-life
assay [28]. Our metabolic studies corroborated the observed effect on metabolism and
demonstrated the likely dominance of cytochromes P450 in metabolisms that are based on
a requirement for NADPH [60]. Surprisingly, the suppressed bioactivation was not due
to the deactivating effects of nitrogen in the ring [57–59], because the distal pyridine and
phenyl substituents did not undergo metabolic activation into reactive quinones (Figure 3).
The observed effect has to be indirect, such as modulations of enzyme specificity possibly
resulting from the pyridine ring being charged at a physiological pH. Alternatively, the
binding mode makes the molecule act more as an inhibitor than a substrate. For the pair
of OXFBD molecules, the overall model scores reflected a decrease in the metabolic bioac-
tivation of OXFBD04 over OXFBD02. This finding aligned with the phenyl to pyridine
substituent effects on quinone bioactivation observed with the molecules present in AMD.
In other words, the quinone model successfully applied the lessons learned from molecules
very different from these BET inhibitors, even if the mechanism for this effect remains
unclear. I-BET-151 also possesses a distal pyridine substituent, but the scaffold is very
different, with the isoxazole linked to a tricyclic moiety making direct comparisons with
the OXFBD molecules impossible.
Metabolism yielded two general possible outcomes for bioactivations; molecules
underwent oxidation into traditional ortho- or para-quinones and novel extended quinone-
methides involving the isoxazole. For the top six predictions, modeled OXFBD bioac-
tivations involved multi-step reactions resulting in an even split between both types of
quinones and their glutathione adducts. Among them, the model predictions highly fa-
vored formation of extended quinone-methides. Overall, four of the six predicted adducts
were verified by experimental studies. Nevertheless, experimental studies showed that
the dominant OXFBD bioactivations were a formation of traditional quinones with ex-
tended quinone-methides being minor metabolites. Moreover, the efforts provided more
insights and evidence for reaction steps and specific pathways. The extensively metabo-
lized OXFBD02 yielded mono- and dihydroxylated metabolites that ultimately fed into
three competing bioactivation pathways (Figure 3). These possibilities arose from hydrox-
ylation of the phenyl scaffold at one of three sites. Further oxidation yielded a reactive
quinone species with two sites of attack by glutathione, so that the subsequent glutathione
trapping led to pairs of adduct isomers. Importantly, hydroxylation of the phenyl ring para
to the isoxazole created an alternate bioactivation pathway leading to an extended quinone-
methide involving both isoxazole and phenyl rings. In contrast, the suppressed metabolism
of OXFBD04 yielded just two mono-hydroxylated metabolites and corresponding reactive
quinones in Pathway 2 (Figure 3). The metabolites of other pathways for OXFBD04 were
beyond the limit of detection for our highly sensitive assay, or simply not present. For
I-BET151, modeled bioactivations were similar in magnitude as those for OXFBD molecules,
yet the pathways led only to extended quinone-methides with a highly reactive methy-
lene group. Unlike those predictions, experimental studies showed minimal I-BET151
metabolism leading to some hydroxylated metabolites and no evidence of any trappable
reactive metabolites. Taken together, modeling was capable of predicting a variety of
quinones including novel extended quinone-methides but fell short of accurately scaling
the likelihood of their formations. Nevertheless, we report the first experimental evidence
for novel extended quinone-methides involving the 3,5-dimethylisoxazole scaffold.
3.4. Novelty and Relevance of Extended Quinone-Methides
Energetically, traditional quinones would be more accessible to oxidative transfor-
mations. Those reactions involve breakage of the aromaticity of the phenyl ring only as
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opposed to the phenyl and isoxazole rings for the extended quinone-methide. In fact,
experimental evidence for an extended quinone species is rare [61]. The most well-known
examples include the selective estrogen receptor modulators (SERMs) raloxifene and arzox-
ifene, in which bioactivation of the benzothiophene scaffold results in extended quinone
species with very short half-lives and, possibly, minimal toxicity [62–66]. In contrast,
bioactivation of the estrogen diethylstilbestrol into an extended quinone species may con-
tribute to the teratogenic effects of the drug, leading to its withdrawal from the market in
1971 [67,68]. It is possible that extended quinone species are more prevalent but escape
detection due to their short half-lives and/or insufficient experimental designs to cap-
ture their formation. Additionally, there is no uniform structure for an extended quinone
species, making detection more challenging. In our case, the quinone model predicted
that all three BET inhibitors underwent bioactivation into an extended quinone species
and we experimentally validated their occurrence for the two OXFBD molecules. Those
findings suggest that formation of the extended quinone-methide may be inherent with
the drug scaffold, albeit a very minor pathway. Nevertheless, if the model scores correlate
with toxicity, then these results may have implications for these drug leads. The modeled
bioactivation scores (0.51 and 0.59) were similar in magnitude to that for estradiol (0.60)
from a previous study by our group [9]. Estradiol is well-known to undergo bioactivation
and induce toxic risks, suggesting those possibilities may exist for OXFBD molecules [69].
3.5. Advances in Isoxazole Bioactivation Studies Revealed Current Limitations of Those Efforts
These modeling and experimental studies provided an uncommon, concerted effort to
study isoxazole bioactivation, but indicated that gaps remain. While very rapid and accessi-
ble, modeling did not accurately scale the relative probabilities of traditional quinones and
extended quinone-methides based on model scores. The molecule-level model output is
well-calibrated, but atom-pair-level scores can lead to underconfident predictions and are
not probabilistic. We partially resolved this problem by computing an optimal threshold for
binarizing scores. In future applications, it may be advantageous to interpret scores as prob-
abilistic for assessing confidence in the predictions. Improving the calibration of pair-level
model predictions may also improve the rankings of inferred metabolites to better reflect
experimental results. Another non-intuitive feature of the quinone model is that atom and
atom-pair scores can be very different. Sometimes high predictions do not correspond to
valid reactive metabolite structures, with atom scores having less reliability than atom-pair
scores. The validity of predictions was improved by using the structure inference model to
filter out highly predicted sites that do not produce an inferred structure. For the experi-
mental studies, analysis of the reactive metabolites relied on set reaction conditions and
no steady-state kinetics that could be used to extrapolate the potential in vivo relevance of
bioactivation pathways [16,18]. Moreover, there are no reported studies investigating and
confirming that the bioactivation of isoxazole-containing molecules contributes to in vitro
or in vivo toxicity. Nevertheless, knowledge of the relative significance of bioactivation
pathways could aid in developing future studies to resolve those issues.
4. Materials and Methods
4.1. Materials
Chemical solvents were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Substrate I-BET151 was purchased from Cayman Chemical (Ann Arbor, MI, USA) and substrates
OXFBD02 and OXFBD04 were synthesized as reported previously [28,31]. Trapping agent
dansyl glutathione trifluoroacetic acid salt was purchased from Toronto Research Chemicals
(Toronto, ON, Canada) while internal standard dansylamide was obtained from Millipore
Sigma. Reducing agent tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was purchased
from Millipore Sigma. Human liver microsomes pooled from 150 donors (HLM150) were
purchased from Corning Gentest (Woburn, MA, USA).
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4.2. Data to Assess Quinone Model Performance toward Isoxazole-Containing Molecules
We identified isoxazole-containing molecules and those undergoing bioactivation
from the literature-derived Accelrys Metabolite Database (AMD) to evaluate model per-
formance. We collected reaction data for all of the isoxazole-containing small molecules
catalyzed within the human liver using SMARTS patterns for the isoxazole ring. We built a
graph database with Neo4j to connect molecules with observed direct and downstream
metabolites up to three metabolic steps away. We queried the graph database to find
conjugated electrophile species involving an isoxazole ring by applying our previously
developed structure inference model, the Metabolic Forest [11], to identify metabolite pairs
formed between the isoxazole-containing molecule and direct or downstream metabolites.
For identified molecule pairs, the upstream isoxazole-containing molecule was annotated
as forming a conjugated electrophile. Then, we queried our graph to determine whether the
isoxazole molecules that form conjugated electrophiles had been experimentally observed
to react with glutathione. We identified 344 isoxazole-containing molecules in AMD. Of
those, 12 molecules formed enimines, and all but one was reactive to glutathione. Some
model evaluation molecules (validation set) were also in model training sets, which may
bias predictions, and therefore we used a hold-out prediction to ensure that we were
evaluating model ability to learn the general principles of the task, rather than memorize
the training data.
4.3. Modeling Bioactivation Pathways for Isoxazole-Containing Molecules
We predicted the complete bioactivation pathways for isoxazole-containing molecules
by coupling models for quinone (conjugated electrophile) formation, metabolite predic-
tion, and molecular reactivity. First, we revealed the bioactivation sites by modeling
the formation of conjugated electrophiles, namely quinones and enimines [9]. This deep
neural network model predicts one- and two-step conjugated electrophile formation by
identifying atom pairs at which metabolic oxidation may occur to form conjugated elec-
trophile metabolites with an accuracy of 88.2% based on a ROC analysis. In this case,
we evaluated the model ability to discriminate between the bioactivated (positives) and
non-bioactivated (negatives) isoxazole-containing molecules. The assessments relied on
the 12 isoxazole-containing molecules undergoing bioactivation (positives) and 332 non-
bioactivated isoxazole-containing molecules (negatives) obtained from AMD. From those
results, we calculated model accuracy with a ROC-AUC score based on (1) comparing
highest bioactivation scores between positives and negatives and (2) proper assignment
of sites for conjugated electrophile formation as recorded in AMD. Second, we used the
quinone model outputs to predict structures for the reactive metabolites using the XenoNet
model and scaled their likelihood based on the quinone model predictions [70]. This model
uses the input molecule to enumerate pathways of metabolite structures while computing
likelihood scores for each pathway. Third, we modeled the reactivity of individual quinone
or enimine metabolites toward glutathione as a trap [10,15]. Our reaction models scale
scores differently, and thus we relied on the quinone model values as the final arbiter of
the possible bioactivation potential for isoxazole-containing molecules. We calculated the
accuracy of the reactivity model based on the ROC-AUC score using the highest atom
score for each molecule and proper identification of the atom reactive toward glutathione,
as recorded in AMD. Lastly, we used the Metabolic Forest model to predict glutathione
adduct structures based on the glutathione rule within its conjugation rule set [11].
4.4. Experimental Bioactivation of Isoxazole-Containing BET Inhibitors as Test Cases
We validated model predictions for the bioactivation of selected BET inhibitors
through experimental approaches. All of the reactions employed metabolism by pooled
human liver microsomes as a model for the average adult human liver. Wells contained
1 mg/mL HLM150, 1 mM dansyl glutathione, and 50 µM substrate in a 100 mM potassium
phosphate buffer with a pH of 7.4 with 0.1% DMSO (co-solvent) and were preincubated
for 5 min at 37 ◦C with shaking at 350 rpm using a BMG Labtech THERMOstar incubator
(Ortenberg, Germany). Reactions were then initiated upon addition of a NADPH regenerat-
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ing system (0.4 µU µL-1 glucose-6-phosphate dehydrogenase, 10 mM glucose 6-phosphate,
2 mM MgCl2, 500 µM NADP+). Identical mixtures without an addition of the NADPH
regenerating system were incubated as negative controls. After 30, 60, or 90 min, aliquots
were quenched by adding an 2-fold volume of ice-cold methanol containing an internal
standard and a reducing agent (10 µM dansylamide and 5 mM TCEP, respectively) and
incubated on ice for 10 min to optimize the precipitation of proteins and a phosphate
buffer [71]. After a 2800× g centrifugation at 4 ◦C for 15 min using a Thermo Scientific Sor-
vall ST 16R Centrifuge (Waltham, MA, USA), the supernatant was transferred to a 96-well
full-volume microplate and evaporated to dryness using an Organomation Associates Mi-
crovap Nitrogen Evaporator System (Berlin, MA, USA). Dried wells were then resuspended
in mobile phase (20:80 H2O:CH3CN + 0.1% formic acid) for HPLC UV/Vis/Fluorescence
and mass spectroscopic analysis, as described in the following section. Each reaction set
was performed in triplicate and replicated two to five times.
4.5. Characterization of BET Inhibitor Reactive Metabolites Trapped as Glutathione Adducts
Reactions were analyzed using LC-fluorescence to infer the yields and LC-MS to character-
ize the structures, as reported previously [19]. Specifically, reaction metabolites were separated
using a 4.6× 150 mm Waters XSelect HSS C18 3.5 µm column heated to 40 ◦C with a Shimadzu
LC-20AB Prominence liquid chromatograph and detected using a Shimadzu RF-10AXL fluores-
cence detector. Mobile phase consisted of Solvents A (0.1% formic acid/90:10 H2O:CH3CN)
and B (0.1% formic acid/CH3CN). A gradient method started with 89% of A and held for
3 min, decreased to 55% of A over 20 min, decreased to 11% of A over 10 min. Solvent A was
then increased back to 89% over 2 min and held for the remainder of the run. Flow rate was
1 mL/min and run time was 38 min. The fluorescence detector was set to excitation at 340 nm
and emission at 525 nm [54,55,72] to detect the dansyl tag. At 15 min, both gain and sensitivity
were increased to improve the visibility of potentially low-yield metabolites. Analyte responses
were normalized to the internal standard dansylamide. We then analyzed the metabolites
and adducts using mass spectrometry to determine the parent masses and fragmentation pat-
terns to validate the purported structures. Samples were injected onto an Agilent Technologic
1290 Infinity HPLC using the same chromatographic method and column as described above.
Analytes were scanned with the Agilent Technologic 6490 Triple Quad LC/MS. The ESI source
was operated in negative and positive ion mode, and ion spectra were acquired in full scan
mode monitoring the m/z range of 100–1200 amu. Subsequently, product ion spectra were gen-
erated from precursor ions with monitoring for fragmentation by collision-induced dissociation
with a collision energy of 30 eV and a range of 45–1000 amu in negative ion mode.
5. Conclusions
Taken together, our computational and experimental studies yielded the first bioac-
tivation evidence for 3,5-dimethylisoxazole-containing BET inhibitors. In the process,
we demonstrated that the deep neural quinone model prediction of enimines indicates
the ability to model multiple types of conjugated electrophiles and thus, have broader
applications. Improvements in model scaling events relative to one another would further
expand on those possibilities. The predicted bioactivation of other novel structural motifs
would flag drug scaffolds early in the drug discovery stage to validate concerns before
committing significant time and resources in their development. For the BET inhibitors,
the occurrence of bioactivations shows a need for subsequent studies to establish relevance
in toxicological mechanisms. The findings in this study provide guidance on the potential
molecular initiating events to establish the relationship between isoxazole substituents,
and their relative bioactivation and subsequent toxic risks. That knowledge can then
guide the selection of structural variants with a safer health outcome profile during drug
development. Importantly, our combined investigative approach provides a method to not
only identify these risks but also facilitate the development of BET inhibitor leads that are
less prone to bioactivations.
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